Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
SYRE
Home
/
SYRE

NASDAQ
$97.459
$97.459

Overview

Price performance
Low
$92.77
High
$98.74
Market open. Last updated: Nov 4, 2026, 8:08 PM UTC
$
97.46
-1.81 (-1.82%)
Average, 50 days
$89.69
$73.87
Open
$96.42
Previous close
$99.27
52-week high
$110.18
Aug 19, 2026 (3 months ago)
52-week low
$21.15
Nov 7, 2025 (13 months ago)
360.80%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
8.99B
Volume
912 934
Total Return (3M)
-7.38%
Total Return (1Y)
322.95%
—
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
spyre.com
Socials
About
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.

Frequently asked questions

SYRE · Spyre Therapeutics, Inc.

01What is Spyre Therapeutics, Inc. stock price today?

The current price of SYRE is $97.46 — it has decreased by 1.82% since the previous close. Data as of Nov 4, 2026.

02Is Spyre Therapeutics, Inc. stock price growing?

SYRE is up 0.43% over the past week, up 4.30% over the past month and up 322.95% over the past year. The price is above its 200-day moving average of $73.87.

03What is Spyre Therapeutics, Inc. market cap?

Spyre Therapeutics, Inc. has a market capitalization of $8.99B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

04What were Spyre Therapeutics, Inc. earnings last quarter?

In its most recent quarterly report, Spyre Therapeutics, Inc. posted a loss of $0.94 per share against an estimate of -$0.785, missing expectations by 19.74%. Upcoming reports are listed in the earnings calendar.

05How volatile is SYRE stock?

In the latest trading session SYRE moved between $92.77 and $98.74, a range of 6.13% of its current price.

06What are SYRE stock 52-week high and low?

Over the past 52 weeks SYRE has traded between $21.15 and $110.18. The current price is 11.55% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.